Skip to main content
SpringerLink
Log in

Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy

  • Case Report
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Atypical femur fracture (AFF) is an uncommon complication of long-term bisphosphonate use, but the risk declines substantially after treatment cessation. We report a case of a 70-year-old woman with osteopenia treated with alendronate for 9 years who presented with right mid-thigh pain and radiographic findings of focal lateral cortical thickening in the right mid-femur and lateral cortex irregularity in the proximal-mid left femur. Alendronate was discontinued, but she remained on estrogen for menopausal symptoms. Four years later, a horizontal linear translucent defect was seen in the right mid-femur area of cortical hypertrophy, consistent with an incomplete AFF. The patient underwent prophylactic intramedullary rodding of the right femur and estrogen was discontinued. Three years later (7 years after initial presentation), the cortical irregularities in the left femur were more prominent and three small horizontal linear translucent defects were now evident, consistent with early incomplete atypical fracture development. The patient also suffered a wrist fracture. She was treated with teriparatide for 1.5 years with resolution of the translucent defects in the left but not the right femur, although abnormal thickening of the lateral cortex persisted in both femurs. Our case demonstrates incomplete atypical femur fracture progression in a patient with long-term bisphosphonate exposure, even after treatment cessation. These findings highlight the importance of follow-up for patients who develop diaphyseal femur stress fractures and the potential for early healing with anabolic therapy. This case also demonstrates the challenge in managing older patients with incomplete AFF at risk for progression to complete AFF and osteoporotic fracture.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg (Br) 89(3):349–353

    Article  Google Scholar 

  2. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294–1301

    Article  CAS  Google Scholar 

  3. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27(12):2544–2550

    Article  Google Scholar 

  4. Lo JC, Grimsrud CD, Ott SM, Chandra M, Hui RL, Ettinger B (2019) Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int 30(12):2515–2520

    Article  CAS  Google Scholar 

  5. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K (2015) Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 86(1):100–107

    Article  Google Scholar 

  6. Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL (2020) Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383(8):743–753

    Article  CAS  Google Scholar 

  7. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23

    Article  Google Scholar 

  8. Lloyd AA, Gludovatz B, Riedel C, Luengo EA, Saiyed R, Marty E, Lorich DG, Lane JM, Ritchie RO, Busse B, Donnelly E (2017) Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci U S A 114(33):8722–8727

    Article  CAS  Google Scholar 

  9. Marshall RA, Mandell JC, Weaver MJ, Ferrone M, Sodickson A, Khurana B (2018) Imaging features and management of stress, atypical, and pathologic fractures. Radiographics. 38(7):2173–2192

    Article  Google Scholar 

  10. Lo JC, Huang SY, Lee GA, Khandewal S, Provus J, Ettinger B, Gonzalez JR, Hui RL, Grimsrud CD (2012) Clinical correlates of atypical femoral fracture. Bone. 51(1):181–184

    Article  Google Scholar 

  11. Lovy AJ, Koehler SM, Keswani A, Joseph D, Hasija R, Ghillani R (2015) Atypical femur fracture during bisphosphonate drug holiday: a case series. Osteoporos Int 26(6):1755–1758

    Article  CAS  Google Scholar 

  12. Png MA, Mohan PC, Koh JSB, Howe CY, Howe TS (2019) Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up. Osteoporos Int 30(12):2417–2428

    Article  CAS  Google Scholar 

  13. Ettinger B, Burr DB, Ritchie RO (2013) Proposed pathogenesis for atypical femoral fractures: lessons from material research. Bone. 55(2):495–500

    Article  CAS  Google Scholar 

  14. Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 52(1):360–365

    Article  CAS  Google Scholar 

  15. Greenspan SL, Vujevich K, Britton C, Herradura A, Gruen G, Tarkin I, Siska P, Hamlin B, Perera S (2018) Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. Osteoporos Int 29(2):501–506

    Article  CAS  Google Scholar 

  16. Zhang HY, Weng HL, Li M, Zhang J (2019) Different surgical outcomes in a patient with bilateral atypical femoral fracture related to bisphosphonate use with or without teriparatide treatment. Osteoporos Int 30(11):2349–2354

    Article  CAS  Google Scholar 

  17. van de Laarschot DM, McKenna MJ, Abrahamsen B et al (2020) Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society. J Clin Endocrinol Metab 105(5):1682–1699

    Article  Google Scholar 

  18. Lo JC, Hui RL, Grimsrud CD, Chandra M, Neugebauer RS, Gonzalez JR, Budayr A, Lau G, Ettinger B (2016) The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone. 85:142–147

    Article  Google Scholar 

  19. Nguyen HH, Lakhani A, Shore-Lorenti C, Zebaze R, Vincent AJ, Milat F, Ebeling PR (2020) Asian ethnicity is associated with atypical femur fractures in an Australian population study. Bone. 135:115319

    Article  CAS  Google Scholar 

  20. Lo JC, Zheng P, Grimsrud CD, Chandra M, Ettinger B, Budayr A, Lau G, Baur MM, Hui RL, Neugebauer R (2014) Racial/ethnic differences in hip and diaphyseal femur fractures. Osteoporos Int 25(9):2313–2318

    Article  CAS  Google Scholar 

Download references

Data sharing

Not applicable for this case report.

Author information

Authors and Affiliations

  1. Department of Medicine, Kaiser Permanente Oakland Medical Center, Oakland, CA, 94611, USA

    K.D. Gu & J.C. Lo

  2. Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA

    B. Ettinger & J.C. Lo

  3. Department of Orthopedic Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA

    C.D. Grimsrud

  4. The Permanente Medical Group, Oakland, CA, 94612, USA

    C.D. Grimsrud & J.C. Lo

Authors
  1. K.D. Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Ettinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C.D. Grimsrud
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J.C. Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J.C. Lo.

Ethics declarations

Ethical approval and informed consent

This study underwent an institutional review process and was deemed not to meet the regulatory definition of research. Patient consent for preparation and publication of this case study was obtained.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

In Memoriam: Bruce Ettinger

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gu, K., Ettinger, B., Grimsrud, C. et al. Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy. Osteoporos Int 32, 2119–2123 (2021). https://doi.org/10.1007/s00198-021-05948-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-021-05948-w

Keywords

Search

Navigation